Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 19.12.2025 UINC IE00BZBW4Z27 10,104,154.00 USD 351,576,628.32 34.795 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Opportunities UCITS ETF 19.12.2025 FPX. IE00BYTH6238 225,002.00 USD 14,087,899.61 62.612 ...
-
Hisense tritt dem HEVC Advance Patentpool bei
BOSTON--(BUSINESS WIRE)--Access Advance LLC, weltweit führend im Bereich der Lizenzierung von Video-Codec-Patentpools, gab heute bekannt, dass Hisense Group Holdings Co., Ltd. dem HEVC Advance Patent Pool als Lizenznehmer beigetreten ist. Hisense schließt sich den jüngsten Neuzugängen zu den Access Advance-Patentpools an, darunter Xiaomi, MSI, Transsion, und baut seine Beziehungen zu Huawei, HP und Sharp aus. Hisense mit Hauptsitz in Qingdao, China, ist einer der weltweit größten Fernsehherstel...
-
Hisense entra a far parte del pool di brevetti HEVC di Advance
BOSTON--(BUSINESS WIRE)--Access Advance LLC, leader globale per le licenze di pool di brevetti per codec video, ha annunciato oggi che Hisense Group Holdings Co., Ltd. è entrato a far parte dei pool di licenze HEVC di Advance. Hisense si unisce alle più recenti aggiunte ai pool di brevetti di Access Advance, che includono Xiaomi, MSI, Transsion, e alle relazioni ampliate con Huawei, HP e Sharp. Hisense, con sede a Qingdao, in Cina, è uno dei più grandi produttori di televisori al mondo, con una...
-
Hisense rejoint le HEVC Advance Patent Pool
BOSTON--(BUSINESS WIRE)--Access Advance LLC, leader mondial dans le domaine des licences de pool de brevets pour codecs vidéo, a annoncé aujourd’hui que Hisense Group Holdings Co., Ltd. a rejoint le HEVC Advance Patent Pool en tant que détenteur de licence. Hisense rejoint ainsi les derniers arrivants dans les pools de brevets Access Advance, parmi lesquels Xiaomi, MSI, Transsion, et renforce ses relations avec Huawei, HP et Sharp. Hisense, dont le siège social est situé à Qingdao, en Chine, es...
-
Granite REIT Notice of Conference Call for Fourth Quarter and Year-End 2025 Results
TORONTO--(BUSINESS WIRE)--Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) expects to announce its financial results for the fourth quarter and year ended December 31, 2025 after the close of markets on Wednesday, February 25, 2026. Granite will hold a conference call and live audio webcast to discuss its financial results. The conference call will be chaired by Kevan Gorrie, President and Chief Executive Officer. Conference Call: Date: Thursday, February 26, 2026 at...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 19.12.2025 GINC LN IE00BD842Y21 710,682.00 USD 41,031,341.16 57.735 ...
-
FRMI INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Fermi Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller is investigating potential violations of U.S. federal securities laws involving Fermi Inc. (NASDAQ: FRMI)....
-
Experian and Influencer Jimmy Darts Bring Financial Empowerment and Holiday Cheer to Consumers
COSTA MESA, Calif.--(BUSINESS WIRE)--Experian® and Jimmy Darts teamed up to give consumers a meaningful boost this holiday season....
-
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE approved in Japan. EKT...